David A. Bristol

Direttore/Membro del Consiglio presso HCF Enterprises, Inc.

Consumer Services

Health Technology

Profilo

David A.
Bristol is currently a Director at HCF Enterprises, Inc. and Sentinel Private Equity XVI Fund.
He was previously a Director at Nanospectra Biosciences, Inc. and a Geophysicist at Exxon Co. USA from 1988 to 1991.
Bristol received his undergraduate degree from Brown University and his graduate degree from The University of Texas at Austin.

Posizioni attive di David A. Bristol

Società	Posizione	Inizio
HCF Enterprises, Inc.	Direttore/Membro del Consiglio	-
Sentinel Private Equity XVI Fund	Direttore/Membro del Consiglio	-

Tutte le posizioni attive di David A. Bristol

Precedenti posizioni note di David A. Bristol

Società	Posizione	Fine
Exxon Co. USA	Corporate Officer/Principal	02/01/1991
Nanospectra Biosciences, Inc. Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di David A. Bristol

Formazione di David A. Bristol

Brown University	Undergraduate Degree
The University of Texas at Austin	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di David A. Bristol

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	4
Nanospectra Biosciences, Inc. Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX.	Health Technology
HCF Enterprises, Inc.
Exxon Co. USA
Sentinel Private Equity XVI Fund

Vedi le connessioni aziendali

Borsa valori
Insiders
David A. Bristol